Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a phase 2 trial. The Bay Area-based biotech unveiled its ambition earlier ...

Maze seeks as much as $133 mln in New York IPO Backers include Alphabet's GV and Third Rock Ventures Biotech IPOs set for ramp up in coming weeks Jan 27 (Reuters) - Drug developer Maze ...

Treat tantrums like anxiety attacks The creator’s game-changing tip involves addressing meltdowns ... In the TikTok, she explains her go-to method: handing her child an ice cube and letting them throw ...

Online games lasting five or more years are hardly unheard of these days, but Warframe has one key difference among that venerable cadre: its days as one of the best free games still seem to be ...